

Takemichi Fukasawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5311858/publications.pdf>

Version: 2024-02-01

38
papers

593
citations

686830

13
h-index

676716

22
g-index

39
all docs

39
docs citations

39
times ranked

555
citing authors

#	ARTICLE	IF	CITATIONS
1	Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease. <i>Journal of Dermatology</i> , 2022, 49, 179-183.	0.6	6
2	Decrease in MAP3Ks expression enhances the cell death caused by hyperthermia. <i>International Journal of Hyperthermia</i> , 2022, 39, 200-208.	1.1	7
3	Predictors of rituximab effect on modified Rodnan skin score in systemic sclerosis: a machine-learning analysis of the DesiReSe trial. <i>Rheumatology</i> , 2022, 61, 4364-4373.	0.9	18
4	Serum C-X-C Chemokine Ligand 1 Levels in Patients with Systemic Sclerosis: Relationship of Clinical and Laboratory Observations to Anti-CD20 Monoclonal Antibody Administration. <i>Life</i> , 2022, 12, 646.	1.1	1
5	Autoantibody Landscape Revealed by Wet Protein Array: Sum of Autoantibody Levels Reflects Disease Status. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	7
6	Pharmacotherapy of Itch Antihistamines and Histamine Receptors as G Protein-Coupled Receptors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6579.	1.8	7
7	Safety and efficacy of rituximab in systemic sclerosis (DESIREs): open-label extension of a double-blind, investigator-initiated, randomised, placebo-controlled trial. <i>Lancet Rheumatology</i> , The, 2022, 4, e546-e555.	2.2	21
8	Serum TARC Levels in Patients with Systemic Sclerosis: Clinical Association with Interstitial Lung Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 660.	1.0	2
9	Development of a prediction model of treatment response in patients with cutaneous arteritis: Insights from a cohort of 33 patients. <i>Journal of Dermatology</i> , 2021, 48, 1021-1026.	0.6	3
10	Safety and efficacy of rituximab in systemic sclerosis (DESIREs): a double-blind, investigator-initiated, randomised, placebo-controlled trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e489-e497.	2.2	105
11	B Cell Depletion Inhibits Fibrosis via Suppression of Profibrotic Macrophage Differentiation in a Mouse Model of Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2021, 73, 2086-2095.	2.9	17
12	Expert-Level Distinction of Systemic Sclerosis from Hand Photographs Using Deep Convolutional Neural Networks. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2536-2539.	0.3	5
13	Serum Calponin 3 Levels in Patients with Systemic Sclerosis: Possible Association with Skin Sclerosis and Arthralgia. <i>Journal of Clinical Medicine</i> , 2021, 10, 280.	1.0	1
14	Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis. <i>Nature Communications</i> , 2021, 12, 5947.	5.8	38
15	Increased Red Blood Cell Distribution Width in the First Year after Diagnosis Predicts Worsening of Systemic Sclerosis-Associated Interstitial Lung Disease at 5 Years: A Pilot Study. <i>Diagnostics</i> , 2021, 11, 2274.	1.3	2
16	COVID-19 pandemic highlighted the importance of telemedicine in the collagen disease of systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 160.	0.4	0
17	Single-cell-level protein analysis revealing the roles of autoantigen-reactive B lymphocytes in autoimmune disease and the murine model. <i>ELife</i> , 2021, 10, .	2.8	32
18	Interleukin (IL) 17F and IL17E are related to fibrosis and vasculopathy in systemic sclerosis. <i>Journal of Dermatology</i> , 2020, 47, 1287-1292.	0.6	9

#	ARTICLE	IF	CITATIONS
19	Rapid decrease of serum surfactant protein- α levels predicts the reactivity of rituximab therapy in systemic sclerosis-associated interstitial lung disease. <i>Journal of Dermatology</i> , 2020, 47, 796-800.	0.6	4
20	Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis. <i>Journal of Dermatology</i> , 2020, 47, 483-489.	0.6	22
21	Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase β -positive systemic sclerosis-associated interstitial lung disease. <i>Journal of Dermatology</i> , 2019, 46, 1006-1013.	0.6	47
22	Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study. <i>Arthritis Research and Therapy</i> , 2019, 21, 129.	1.6	29
23	Serum levels of human defensin 2: possible association with fibrosis and vasculopathy in patients with systemic sclerosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e272-e274.	1.3	2
24	Prevention of calpain-dependent degradation of STK38 by MEK2-mediated phosphorylation. <i>Scientific Reports</i> , 2019, 9, 16010.	1.6	7
25	Cytokine analysis on a countable number of molecules from living single cells on nanofluidic devices. <i>Analyst</i> , 2019, 144, 7200-7208.	1.7	39
26	Assessment of endothelial function during the loading phase of infliximab in psoriasis: a potential predictor of its drug survival. <i>International Journal of Dermatology</i> , 2019, 58, 54-59.	0.5	5
27	Exacerbated Immune Complex-Mediated Vascular Injury in Mice with Heterozygous Deficiency of Aryl Hydrocarbon Receptor through Upregulation of Fc γ Receptor III Expression on Macrophages. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2195-2204.	0.3	1
28	Successful treatment with rituximab in a Japanese patient with systemic sclerosis-associated interstitial lung disease resistant to oral steroid and cyclophosphamide. <i>Journal of Dermatology</i> , 2018, 45, e140-e141.	0.6	3
29	Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease. <i>Journal of Dermatology</i> , 2018, 45, 1221-1224.	0.6	8
30	Serum interleukin-34 levels in patients with systemic sclerosis: Clinical association with interstitial lung disease. <i>Journal of Dermatology</i> , 2018, 45, 1216-1220.	0.6	16
31	060 The cytokine production of autoantigen-reactive B cells associates with pathogenesis in systemic sclerosis. <i>Journal of Investigative Dermatology</i> , 2018, 138, S10.	0.3	0
32	Critical contribution of the interleukin-6/signal transducer and activator of transcription 3 axis to vasculopathy associated with systemic sclerosis. <i>Journal of Dermatology</i> , 2017, 44, 967-971.	0.6	14
33	Unprecedented success of rituximab therapy for prednisolone- and immunosuppressant-resistant systemic sclerosis-associated interstitial lung disease. <i>Scandinavian Journal of Rheumatology</i> , 2017, 46, 247-252.	0.6	9
34	Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1879-1890.	2.9	47
35	Single B cell analysis can reveal distinct cytokine profile of autoreactive B cells in systemic sclerosis. <i>Journal of Dermatological Science</i> , 2017, 86, e7-e8.	1.0	1
36	Nucleosome in patients with systemic sclerosis: possible association with immunological abnormalities via abnormal activation of T and B cells. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1858-1865.	0.5	12

#	ARTICLE	IF	CITATIONS
37	Serine/Threonine Kinase 38 regulates CDC25A stability and the DNA damage-induced G2/M checkpoint. Cellular Signalling, 2015, 27, 1569-1575.	1.7	22
38	The HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin modulates radiosensitivity by downregulating serine/threonine kinase 38 via Sp1 inhibition. European Journal of Cancer, 2013, 49, 3547-3558.	1.3	24